SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
EnVivo Pharmaceuticals, Inc. Presents Additional EVP-6124 Phase 2b Clinical Trial Results at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting